Combining CDK4/6 inhibitors with PI3K/mTOR inhibitors can significantly slow tumor growth in animal models, suggesting that PI3K/mTOR inhibitors can help restore sensitivity to CDK4/6 inhibitors. Here, PIK3CA is linked to neoplasm.